In 2025, North America emerged as the clear frontrunner in the healthcare Contract Research Organization (CRO) market  and it’s easy to see why! 🏆🇺🇸 The region is home to some of the world’s most powerful pharmaceutical giants, and American consumers continue to enjoy access to the most cutting-edge medical products available, even if it comes at a premium.

As these pharma and biotech companies grow, they’re increasingly outsourcing clinical trials and research activities to specialized CROs to accelerate innovation and stay competitive.

One major reason for this boom is the rapid rise of the biotech sector in North America. With significant venture capital flowing into medical startups, the region is becoming a hotbed for groundbreaking research and development. For instance, in 2023 alone, over $20 billion was raised to fuel new biotech ideas — with startups like Beam Therapeutics making major waves in the industry.

Another driving factor is the unique government framework in North America, especially the U.S. FDA’s role. The regulatory approach here manages to strike a fine balance between encouraging revolutionary new treatments and ensuring patient safety.

✨ Example in Action: PharmaLegacy’s Strategic Move
In September 2024, PharmaLegacy  a well-established CRO providing preclinical pharmacology solutions  made a major move by acquiring BTS Research. 🧫🤝 This acquisition isn’t just about expansion; it’s about tapping into the vibrant research ecosystem of San Diego, one of the world’s leading R&D hubs. 🌐🏙️

Through this deal, PharmaLegacy gains a stronger global footprint and the ability to offer an even broader range of services to clients around the world. 🌍📊 It’s a strategic step forward, showcasing how North American CROs are evolving to meet the future of healthcare head-on.

Request a customized case study tailored to your business needs and gain deeper insights into healthcare market strategies: sales@towardshealthcare.com